Nuance Labs, a Seattle-based artificial intelligence startup developing a foundational AI model designed to perceive and respond to real-time human expression, raised $50 million in Series A funding.

Founded in early 2025 by former Apple PhD researchers Fangchang Ma, Edward Zhang, and Karren Yang, the research lab is developing a single “full-duplex” foundation model designed to process and generate conversational cues simultaneously.

Unlike traditional setups that chain together separate tools for transcription, text generation, and voice or animation, Nuance’s model ingests live audiovisual signals like tone, gaze, and timing to stream real-time facial and vocal responses.

Existing avatars and voice tools fail because they force humans to adapt to the machine rather than the other way around, according to Ma, Nuance’s CEO.

“The most productive collaboration comes from being able to express yourself freely, in words, tone, gesture, and expression, the way you would with a friend or close colleague, with all the nuance in the back-and-forth that turns talking into understanding,” Ma said in a news release. “That’s what we’re building at Nuance Labs: AI that understands the many ways we express ourselves and responds the way a person does, in the moment.”

In a demo video accompanying the announcement (below), the startup showcased an avatar built to function as an active listener, adjusting its facial expressions and verbal cues dynamically as the user speaks.

Zhang, Nuance’s CTO, earned his PhD in computer graphics from the University of Washington and met Ma at Apple’s engineering office in Seattle. The two spoke to GeekWire last fall about building in Seattle rather than Silicon Valley and how they want Nuance “to be the premier research lab in Seattle.”

The startup plans to release a public research preview of its model later this year, giving users their first hands-on test of the interactive face-to-face avatar. Nuance targets applications where real-time human expression drives outcomes, including sales, customer service, professional coaching, and education.

Returning investor Lightspeed Venture Partners led the round, which also included participation from existing backers Accel and South Park Commons, alongside new investments from NVIDIA and Define Ventures.

The financing brings Nuance Labs’ total capital raised to $60 million following its $10 million seed round last year.

Nuance, which lists 24 employees on its website, plans to use the fresh capital to accelerate model development and hire researchers and engineers across modeling, data, evaluation, and real-time serving as it expands its team.

Obama recently said that Democrats need to make artificial intelligence one of their “central agendas” and “have a very clear plan” to address concerns around the technology’s economic impact and safety.

Seven courses from White Belt through Black Belt certification give operations teams 38 hours of training.

The post Your Team’s Lean Six Sigma Training, Now $35 appeared first on TechRepublic.

Seattle biotech startup BrainChild Bio has raised $116 million to advance an experimental CAR T cell therapy for one of the deadliest forms of childhood brain cancer.

The Series A financing will primarily fund a pivotal Phase 2 clinical trial of an investigational therapy being developed for diffuse intrinsic pontine glioma, or DIPG. The rare brainstem tumor primarily affects children ages 5 to 10 and has few treatment options.

The financing was led by an undisclosed private family fund and foundation, with participation from BrainChild Bio’s initial investor, Seattle Children’s, and new investor WRF Capital.

BrainChild Bio is building on CAR T cell technology developed at Seattle Children’s and licensed exclusively to the company in 2023. The approach involves genetically engineering a patient’s own T cells to recognize and attack cancer cells.

The company says its new therapy has now entered its ILLUMINATE Phase 2 study, designed as a registration-stage trial that could eventually support an application to the U.S. Food and Drug Administration.

DIPG presents a particularly difficult challenge for cancer researchers because the tumors grow in the brainstem, an area critical to basic functions, and the blood-brain barrier can limit the ability of treatments to reach the tumor.

BrainChild Bio’s approach delivers the CAR T cells directly into cerebrospinal fluid through an implanted catheter, allowing the cells to reach the tumor locally and potentially be administered repeatedly.

About 300 children in the U.S. are diagnosed with DIPG each year, a devastating brain tumor with no cure and few treatment options. Radiation is the current standard of care, but children diagnosed with DIPG have a median overall survival of only about 11 months.

BrainChild Bio also plans to use proceeds from the new financing to advance a CAR T therapy designed to target three different cancer markers, toward initial clinical testing in glioblastoma.

The company was founded by Michael Jensen, who previously helped develop the underlying work at Seattle Children’s and was a co-founder of Umoja Biopharma and Juno Therapeutics. The CEO is Steven Brugger, who most recently served as founder and CEO of Affinivax, a biotech company which was acquired by GSK for $3.3 billion in 2022. 

“This financing enables us to chart our path forward to serve the children and families afflicted with devastating brain tumors and represents a new paradigm for treating CNS brain tumors in children and adults,” Jensen said in a statement. “Our team at BrainChild Bio is steadfast in its commitment to harness CAR T cell technology in CNS tumors and we are uniquely positioned to do so.”

Firefox, GIMP, and LibreOffice are the obvious, popular apps that you'll see everyone recommend for your Linux system. But there are many more apps beyond those.

Open-source software is wonderful: it's free, diverse, and surprisingly accessible. You might feel that software development is a secret world of privilege and insider knowledge, but OSS has made great strides to overturn this misunderstanding.

If you've been in the Linux space for a while, you know just how customizable KDE Plasma can be. However, a lot of us only limit that customization to picking the theme or moving the panel. What surprises me is how many plug-in surfaces Plasma exposes that I barely even touched. On top of that, they sit right next to the Plasma features you probably use daily.

Compare the best UCaaS providers for 2026, including pricing, features, use cases, and how to choose the right unified communications platform.

The post 6 Best UCaaS Providers in 2026 appeared first on TechRepublic.

The first Japanese citizen to launch into space, Toyohiro Akiyama was also the first commercially sponsored cosmonaut and the world's first journalist to file reports while on a spaceflight.

Akiyama, 84, died last Wednesday, August 26, of lower gastrointestinal bleeding, news agencies in Japan reported. A funeral was held with his close relatives in attendance.

As a correspondent for the Tokyo Broadcasting System (TBS), Akiyama was chosen out of his 162 fellow employees who applied to fly to space in celebration of the network's 40th anniversary. He trained at the Gagarin Cosmonaut Training Center in Star City, located outside of Moscow, and was assigned to the Soyuz TM-11 crew.

Read full article

Comments

© Roscosmos

A Kirkland, Wash.-based biotech company led by former Athira Pharma CEO Leen Kawas has raised $35 million in a Series A round led by Propel Bio Partners, the Los Angeles investment firm where Kawas is a co-founder and managing general partner.

EIT Pharma said Monday that the oversubscribed round also drew participation from Good Ventures, Arrowtown and others. The company said the money will support FDA review of lonafarnib, an oral treatment candidate for chronic hepatitis D, along with manufacturing and commercial preparations, subject to regulatory approval.

The Food and Drug Administration accepted the company’s New Drug Application for review on Aug. 11.

Lonafarnib came to EIT Pharma through the 2024 bankruptcy of Eiger BioPharmaceuticals, in a court-supervised sale that closed that September. The same sale included peginterferon lambda, which EIT Pharma is developing for severe respiratory infections.

Kawas, EIT Pharma’s CEO, said in a news release Monday that the oversubscribed round validates the company’s founding belief that “advancing important medicines is about recognizing unrealized potential.”

Chronic hepatitis D is a serious liver disease that affects people who are already infected with hepatitis B. The FDA approved the first U.S. treatment for chronic hepatitis D in May: Gilead’s injectable Hepcludex, or bulevirtide-gmod. EIT Pharma is positioning lonafarnib as a potential oral alternative, if approved.

Kawas resigned as CEO of Athira Pharma in 2021 after a board investigation found she had altered images in research she co-authored as a graduate student. She said at the time that the changes were enhancements that did not alter the underlying data.

Athira has since changed its name to LeonaBio and shifted its focus from Alzheimer’s disease to breast cancer.